

# Dolutegravir - SAILING Data Confirms Best in Class Integrase Inhibitor - More Threat to Elvitegravir than Raltegravir

https://marketpublishers.com/r/D76CFF0D955EN.html

Date: March 2013 Pages: 3 Price: US\$ 90.00 (Single User License) ID: D76CFF0D955EN

## **Abstracts**

Dolutegravir - SAILING data confirms best in class integrase inhibitor - More threat to Elvitegravir than Raltegravir

Clinical data from PhIII SAILING study announced yesterday demonstrated dolutegravir's statistically significant superiority as compared to Isentress in treatment experienced HIV patients. The data confirms best in class clinical profile of dolutegravir with once daily advantage amongst integrase inhibitors (Raltegravir, Elvitegravir). MRK's raltegravir (Isentress) is the only integrase inhibitor on the market (2012 sales \$1.3b) and ~90% of its total worldwide sales comes from the treatment experienced patient pool. We forecast ..........The Market Dynamics - once all three Integrase inhibitors are on the market Dolutegravir launch is expected in August 2013 (PDUFA – August 17th-2013) and we expect it to initially grab a share......

#### **Companies mentioned**

GlaxoSmithKline, Pfizer, Merck, Shionogi



#### I would like to order

Product name: Dolutegravir - SAILING Data Confirms Best in Class Integrase Inhibitor - More Threat to Elvitegravir than Raltegravir

Product link: https://marketpublishers.com/r/D76CFF0D955EN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/D76CFF0D955EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Dolutegravir - SAILING Data Confirms Best in Class Integrase Inhibitor - More Threat to Elvitegravir than Ralt...